ArticleJournal of applied toxicology : JAT2026
An In Vitro and In Vivo Assessment of the Genotoxic Potential of Maizinol (UP165), a Zea mays Leaf Extract.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An In Vitro and In Vivo Assessment of the Genotoxic Potential of Maizinol (UP165), a Zea mays Leaf Extract.Journal of applied toxicology : JAT · 2026Article
- An Evaluation of Oral Subchronic Toxicity of Maizinol (UP165), a Zea mays Leaf Extract.Journal of applied toxicology : JAT · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Benzoxazinoids are secondary metabolites produced in monocotyledons and some dicotyledons from the Acanthaceae, Ranunculaceae, Scrophulariaceae, Plantaginaceae, and Lamiaceae families. Benzoxazinoids are commonly consumed in bread and cereal products that have been ingested for decades, which supports the safe use of benzoxazinoids as food ingredients. Powdered corn leaf extract (UP165), trade name Maizinol, containing 0.2%-0.3% w/w benzoxazinoid 6-methoxy-2-benzoxazolinone (6-MBOA), was the subject of genetic toxicity studies conducted according to Organisation for Economic Co-operation and Development (OECD) Test Guidelines (TG). The toxicity tests evaluated the safety of corn leaf extract (as Maizinol containing 0.2%-0.3% 6-MBOA) using a bacterial reverse mutation assay (OECD Test Guideline 471) at doses of 313, 625, 1250, 2500, or 5000 μg/plate; in vitro mammalian chromosomal aberration test (OECD TG 473) at concentrations of 9.77, 19.5, 39.1, or 78.1 μg/mL; and in vivo mammalian erythrocyte micronucleus test (OECD TG 474) at a dose of 750, 1500, or 3000 mg/kg body weight/day. Results demonstrate that Maizinol (UP165), at maximum test concentrations of 5000 μg/plate in the bacterial mutagenicity study, 78.1 μg/mL in the mammalian chromosomal aberration test, and a dose of 3000 mg/kg body weight in the rat micronucleus test, did not elicit genotoxic or mutagenic effects under the reported test conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.